Clara Rodríguez Fernández, Author at Labiotech.eu

About

Traveler, musician, food enthusiast and book worm. Always on the hunt for interesting facts and news.

Articles by Clara Rodríguez Fernández

News and Trends 15 May 2018

An Epigenetic Drug for Prostate Cancer Gets $26M to Enter Clinical Trials

CellCentric has raised a private round to fund the development of a first-in-class drug with potential to tackle treatment-resistant prostate cancer. Cambridge-based CellCentric has raised $26M from Morningside Venture Investments. The company plans to use the cash to fund the development of an epigenetic cancer drug up to Phase 2b trials. The drug in question, called CCS1477, […]

May 15, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 14 May 2018

German Biotech Expands Oncology Deal with Bluebird bio to $1.5Bn

Medigene and bluebird bio are increasing the number of cancer targets against which to develop TCR candidates, raising their already huge deal to a massive $1.5Bn. In September 2016, Medigene and bluebird bio partnered to develop T cell receptor-modified T cells (TCR-Ts) as candidates for cancer immunotherapy treatments. Medigene was offered up to $250M per each of […]

May 14, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 8 May 2018

Scottish Biotech Boosts its CAR-T Pipeline for Cancer and HIV

TC Biopharm has partnered with Scotia Biologics to produce tumor-specific antibodies for a new generation of safer CAR-T therapies against multiple types of tumors as well as viral infections such as HIV. The Scottish biotech TC Biopharm will be working with its new partner Scotia Biologics on the development of CAR-T therapy candidates against neuroblastoma, […]

May 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

cambridge cancer genomics liquid biopsy ai

Interview 2 May 2018

Combining Liquid Biopsy and Artificial Intelligence to Outrun Cancer

Making liquid biopsy and artificial intelligence technologies work together could help doctors make faster decisions to treat cancer on time. Philip talked to the CEO of Cambridge Cancer Genomics to find out what this approach can mean for the treatment of cancer. Although much progress has been made in recent years, cancer remains one of […]

May 2, 2018 - 4 minutesmins - By Clara Rodríguez Fernández

News and Trends 19 Apr 2018

“This is the First Time CAR-T Has Ever Worked on Acute Myeloid Leukemia“

Celyad has reported clinical results showing the first time a patient has fully recovered from acute myeloid leukemia thanks to a CAR-T therapy, and without the need for chemotherapy preconditioning. At the AACR meeting in Chicago this week, Celyad has presented preliminary data from three of its ongoing Phase 1 clinical trials with a new […]

April 19, 2018 - 3 minutesmins - By Clara Rodríguez Fernández

In Depth 9 Apr 2018

Are PD-1 and PD-L1 Checkpoint Inhibitors As Good As We Thought?

Checkpoint inhibitors, especially those targeting PD-1 and PD-L1, are exploding in popularity. But how much of it is hype? The pipelines of biotech and pharma are filling up with combination therapies for anti-PD-1 and PD-L1 antibodies. According to the Cancer Research Institute, there are now over 1,500 clinical trials testing the popular checkpoint inhibitors, a dramatical increase […]

April 9, 2018 - 4 minutesmins - By Clara Rodríguez Fernández

OSE Immunotherapeutics Boehringer Ingelheim

News and Trends 5 Apr 2018

Boehringer Offers €1Bn for New Checkpoint Inhibitor from a French Biotech

OSE Immunotherapeutics could receive up to €1.1Bn from its new partner Boehringer Ingelheim, which has set its eyes on a new type of checkpoint inhibitor being developed by the French biotech. OSE Immunotherapeutics has entered a global license and collaboration deal with Boehringer Ingelheim for the development of OSE-172, a checkpoint inhibitor antibody to treat […]

April 5, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

genesight gene therapy blindness placebo

News and Trends 4 Apr 2018

Placebo Beats a Gene Therapy for Blindness in a Phase 3 Trial

GenSight has demonstrated that its gene therapy for a rare disease causing blindness can significantly improve the vision of patients. But so does the placebo. GenSight Biologics has released the results of a Phase III clinical trial testing its gene therapy GS010 in patients suffering from Leber hereditary optic neuropathy (LHON), a rare mitochondrial disease […]

April 4, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Interview 3 Apr 2018

Seven Expert Tips on How to Grow a Successful Biotech Startup

The journey to create and grow a successful biotech startup is long and carries a high risk of failure. I decided to explore the main pitfalls that biotech entrepreneurs find and how to avoid them. Biotech startups can bring solutions to some of the biggest problems in the world, making some bucks along the way. […]

April 3, 2018 - 8 minutesmins - By Clara Rodríguez Fernández

Infographics 2 Apr 2018

Infographic: All You Need to Know About Cultured Meat

You might have heard about a new type of meat that can be produced without harming animals or harming the environment. This infographic will show you everything you need to know about cultured meat, which might be on your plate sooner than you think. In the not-so-distant future, the vegan diet might include meat. Researchers […]

April 2, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Startup Scout 30 Mar 2018

This French Biotech Detects Microbes With a “Molecular Hook”

Today we are in the sunny Marseille, on the South coast of France, visiting Click4Tag, a biotech developing a molecular hook to attach to and detect microbial membranes. Its unusual principle has both environmental and medical applications. Mission: Founded in 2014, Click4Tag is developing a unique technology to detect microorganisms. The company introduces a “molecular hook” into […]

March 30, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 29 Mar 2018

Cancer Trial Halted in the UK After Overdosing First Patient

Redx Pharma has temporarily interrupted recruitment in a Phase I/IIa cancer trial following “significant adverse events” of its drug on the first patient treated. The first time Redx Pharma’s cancer drug RXC004 has been tested in a patient has resulted in adverse side effects. According to Redx, the dose tested resulted in a higher exposure […]

March 29, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us